FDA licenses Acambis' ACAM2000 vaccine for protection against smallpox
Acambis plc announced that the US food and Drug Administration (FDA) has approved its ACAM2000 (smallpox (Vaccinia) Vaccine, Live) vaccine for active immunisation against smallpox disease for persons determined to be at high risk for smallpox infection. This approval is a key step towards Acambis finalising a long-term "warm-base manufacturing" contract with the US Government.
Acambis developed ACAM2000 under contracts with the US Centers for Disease Control and Prevention (CDC) as part of its preparations for a public health emergency. ACAM2000, which is a single-dose vaccine, is the primary smallpox vaccine for use in an emergency and forms the majority of the US Government's smallpox vaccine Strategic National Stockpile (SNS). To date, Acambis has supplied 192.5 million doses of ACAM2000 to the CDC for the SNS.
Acambis is currently in advanced negotiations with the CDC for a "warm-base manufacturing" contract to provide the US Government with a long-term ACAM2000 production capability that is located entirely in the US. The contract would also cover licence maintenance activities.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.